Lamotrigina Mylan

Lamotrigine, the active ingredient in Lamotrigina Mylan, is an anticonvulsant presented as an oral tablet for oral use. It is employed in the management of epilepsy and as a mood stabilizer in bipolar disorder, helping to reduce seizure frequency and mood swings.

GNH USA supplies Lamotrigina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Products are manufactured under EU GMP guidelines and undergo comprehensive testing before release.

Lamotrigine is used in the treatment of seizure disorders and mood stabilization, acting on neuronal excitability.

- Epilepsy: Used as monotherapy or adjunctive therapy to lower the frequency and severity of both partial and generalized tonic‑clonic seizures in adult and pediatric patients. - Bipolar disorder: Employed as a mood stabilizer to prevent recurrence of manic and depressive episodes, contributing to long‑term maintenance therapy in patients with bipolar I disorder.

Lamotrigine may be associated with a range of adverse reactions, varying in frequency and severity. These events can affect patients differently and may require medical attention.

Common Side Effects: - Dizziness - Headache - Nausea - Rash - Blurred vision - Fatigue

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Aseptic meningitis - Severe hypersensitivity reactions (e.g., drug reaction with eosinophilia and systemic symptoms) - Blood dyscrasias such as agranulocytosis

When prescribing lamotrigine, several precautionary measures should be considered to ensure patient safety.

- Initiation: Start with a low dose and increase gradually to reduce risk of skin reactions. - Concomitant valproate: Dose may need adjustment as valproate can increase lamotrigine levels. - Hormonal contraception: Oral contraceptives can lower lamotrigine concentrations, requiring monitoring. - Renal or hepatic impairment: Use with caution and consider dose modification in patients with organ dysfunction. - History of rash: Avoid use in individuals with prior severe cutaneous reactions to lamotrigine or similar agents. - Store at ambient temperature: Keep below 25°C, in the original container, protected from moisture and light.

Lamotrigine interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Valproic acid: Significantly raises lamotrigine levels, increasing risk of adverse effects. - Carbamazepine, phenytoin, phenobarbital: Induce metabolism, markedly lowering lamotrigine concentrations. - Oral contraceptives (estrogen‑containing): Reduce lamotrigine exposure, potentially diminishing efficacy.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., SSRIs, SNRIs): May increase risk of serotonin syndrome. - Antiepileptic drugs that affect hepatic enzymes (e.g., topiramate, zonisamide): May require dose adjustments. - Immunosuppressants (e.g., ritonavir): Can alter lamotrigine metabolism.